Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc (SMTI) specializes in advanced collagen-based solutions for surgical and chronic wound care, serving healthcare providers through clinically validated technologies. This hub provides investors and medical professionals with centralized access to official corporate developments.
Key Resources: Track FDA clearances for medical devices, quarterly earnings reports detailing commercialization progress, and strategic partnership announcements with healthcare distributors. All content is sourced directly from company filings and verified press releases.
Content Types Include: Product launch details for wound care innovations, financial performance updates, clinical study outcomes, and executive leadership changes. Materials are organized chronologically for historical analysis and trend identification.
Staying Informed: Bookmark this page or check regularly for unedited primary source materials about SMTI's market position in medical technology. Cross-reference with regulatory databases for complete context on product approvals.
Sanara MedTech Inc. (NASDAQ: SMTI) reported preliminary 2021 financial results, showing a substantial increase in revenues. For Q4 2021, total revenue reached approximately $7.0 million, up 47% from $4.8 million in Q4 2020. Full-year revenue was approximately $24.1 million, a 55% increase from $15.6 million in 2020. The growth is attributed to expanding the sales force and distribution network. As of December 31, 2021, cash and cash equivalents stood at $18.7 million.
Sanara MedTech Inc. (NASDAQ: SMTI) has appointed Zachary B. Fleming as Chief Executive Officer effective January 1, 2022. Ron Nixon, Executive Chairman, praised Fleming's leadership, highlighting his role in achieving double-digit revenue growth in the Surgical Division amidst the COVID-19 challenges. Fleming aims to enhance Sanara's surgical offerings and execute its comprehensive wound and skin care strategy. With a background in sales and management roles at the company and previous firms, Fleming's appointment is expected to foster innovation and improve stakeholder outcomes.
Sanara MedTech (NASDAQ: SMTI) announced the resignation of J. Michael Carmena as Principal Executive Officer and Board member, effective December 31, 2021. Eric Tanzberger will join the Board on January 1, 2022, bringing extensive finance and corporate governance experience. Ron Nixon, Executive Chairman, praised Carmena's leadership and expressed gratitude for his contributions. Tanzberger's appointment is expected to enhance Sanara's strategic growth in wound and skin care markets.
Sanara MedTech Inc. (NASDAQ: SMTI) announced Roszell Mack III has been appointed to its Board of Directors, effective January 1, 2022. Mack brings extensive experience in finance and technology ventures, and is expected to provide valuable insights as the company executes its wound and skin care strategy. He is the President of Mack & Co., LLC, and previously co-founded Ascend Venture Group. His background includes over a decade in investment banking at Goldman Sachs and Salomon Smith Barney, making him a significant addition to the board.
Sanara MedTech reported strong financial results for Q3 2021, with revenues of $5.8 million, a 35% increase from the previous year. Despite the impact of COVID-19 Delta variant causing elective procedure delays, the company gained new hospital approvals and expanded its sales team to 29 members. However, net losses increased to $2 million due to rising selling, general, and administrative expenses, totaling $6.9 million. The company is optimistic that postponed procedures will eventually be performed. A conference call is set for November 15, 2021.
Sanara MedTech Inc. (NASDAQ: SMTI), based in Fort Worth, Texas, has announced the commercial launch of two innovative products in collaboration with Cook Biotech Inc. These products, FORTIFY TRG™ Tissue Repair Graft and FORTIFY FLOWABLE™ Extracellular Matrix, are designed to enhance surgical and chronic wound care. Both products are FDA 510(k) cleared, with FORTIFY TRG aimed at reinforcing soft tissue and FORTIFY FLOWABLE designed for various wound management applications. The partnership aims to improve patient outcomes while reducing costs.
Sanara MedTech Inc. (NASDAQ: SMTI) announced its third quarter earnings release will occur on November 12, 2021, after market close. A conference call is scheduled for November 15, 2021, at 9:00 a.m. ET. Investors can access the call by dialing 888-506-0062 or via the company's website for a live webcast. The company focuses on advanced wound care solutions and aims to improve patient outcomes through innovative products and telemedicine services. Key areas of focus include biofilm removal and advanced biologics.
Sanara MedTech Inc. (NASDAQ:SMTI), a Fort Worth-based provider of surgical and chronic wound care products, announced its virtual presentation at the 2021 Cantor Virtual Global Healthcare Conference. The presentation is scheduled for September 29, 2021, at 9:20 a.m. ET. Prior to the event, presentation materials will be available on the company's Investor Relations website. Sanara focuses on evidence-based healing solutions, offering products like CellerateRX® and BIAKŌS™ for wound care, while also expanding into telemedicine for consultations.
Sanara MedTech Inc. (NASDAQ: SMTI) has been selected to present at the virtual MicroCap Leadership Summit on September 24, 2021. Executive Chairman Ron Nixon will represent the company among ten selected firms, connecting with over 100 retail and institutional investors globally. Sanara specializes in surgical and chronic wound care products, aiming to improve patient outcomes. The presentation materials will be accessible on the company's website before the event. For further details, visit MicroCapClub.
Sanara MedTech Inc. (NASDAQ:SMTI) reported significant growth in its second quarter results for 2021. Revenues reached $6.28 million, up 112% from the previous year, driven by increased sales of surgical products across more facilities. The company expanded its sales team and formed a strategic partnership with Pixalere Healthcare. Despite a net loss of $1.21 million for the quarter, improvements were noted compared to the prior year. Sanara also acquired assets from Rochal Industries, enhancing its R&D capabilities.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
